Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clobetasol propionate
Drug ID BADD_D00490
Description Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors.[L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974.[A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809]
Indications and Usage For short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.
Marketing Status Prescription; Discontinued
ATC Code D07AD01
DrugBank ID DB01013
KEGG ID D01272
MeSH ID D002990
PubChem ID 32798
TTD Drug ID D0H0YD
NDC Product Code 63629-8637; 63739-064; 43538-950; 71589-004; 0168-0301; 50742-304; 43538-951; 50383-269; 63629-8639; 50383-267; 68071-1599; 0378-8055; 71589-002; 63629-2395; 50383-978; 49452-2141; 51672-1258; 71589-003; 63629-2393; 50383-270; 50090-4146; 0781-7137; 70700-106; 70518-2068; 71085-007; 46439-8747; 45802-637; 45802-961; 72189-262; 0299-3848; 0378-8147; 62559-980; 40032-028; 0472-0400; 16714-992; 70752-153; 62332-547; 68071-4706; 76003-0325; 71589-007; 51672-1347; 52565-051; 0168-0163; 50090-2289; 43386-096; 51672-4193; 0299-3847; 0378-8167; 33342-321; 52128-158; 70710-1401; 51672-1371; 63629-2330; 0299-3849; 0472-0404; 68462-625; 59088-762; 68788-7768; 52565-082; 70700-109; 70771-1498; 68788-7212; 68040-713; 10337-163; 69238-1732; 42291-076; 63629-2332; 0168-0269; 40032-096; 0472-0403; 63629-2392; 68462-532; 51672-1293; 71428-005; 62991-1492; 63629-2331; 71205-151; 50090-5778; 51672-1297; 70771-1209; 66993-939; 51672-1350; 52565-094; 68180-956; 68462-530; 64958-0101; 62332-425; 0168-0293; 69238-1532; 45802-437; 68462-608; 22552-0006; 79572-008; 16714-730; 62332-486; 13668-603; 50383-266; 70518-1178; 50090-5264; 70771-1080; 0713-0656; 51927-2627; 60429-901; 45802-925; 50090-5488; 51672-1294; 49502-537; 60432-133; 62332-465; 0168-0162; 50090-4630; 70710-1456; 50090-3820; 72578-085; 13668-569; 43538-953; 16714-030; 43538-952; 68462-529; 51552-0605; 68180-536; 63629-2329; 10337-162; 42571-362; 69482-700; 50383-268; 42291-077; 0378-8182; 64980-441; 50090-4647; 50090-5079; 68462-480; 52565-055; 50090-2405; 68180-551; 0472-0402; 51672-1259; 0591-4039; 63646-500; 63629-8638; 16714-782; 50383-979; 63629-2394; 52565-039; 60429-902; 46439-8708; 68382-998; 43386-028; 68071-1600; 68788-7581; 62332-548; 70771-1442; 71589-006; 50090-0548
Synonyms Clobetasol | Clofenazon | Clobetasol Propionate | Clobetasol 17-Propionate | Clobetasol 17 Propionate | Clobex | Cormax | OLUX | Dermovate | Embeline | Embeline E | Temovate
Chemical Information
Molecular Formula C25H32ClFO5
CAS Registry Number 25122-46-7
SMILES CCC(=O)OC1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)C(=O)CCl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash23.03.13.0010.000797%Not Available
Rash pustular11.01.12.002; 23.03.10.003--
Rosacea23.02.08.001--Not Available
Seborrhoea23.02.07.0010.000399%Not Available
Secondary adrenocortical insufficiency14.11.01.014; 05.01.02.003--Not Available
Septic shock24.06.02.011; 11.01.11.0040.000104%Not Available
Skin atrophy23.01.05.0010.001063%
Skin discomfort23.03.03.006--Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.0030.000399%Not Available
Skin fissures23.03.03.008--Not Available
Skin hyperpigmentation23.05.01.0030.000266%
Skin hypertrophy23.01.04.002--Not Available
Skin hypopigmentation23.05.02.003--
Skin irritation23.03.04.0090.000266%Not Available
Skin striae23.01.05.0020.000399%Not Available
Squamous cell carcinoma of skin23.08.02.005; 16.03.02.0050.000243%Not Available
Telangiectasia24.03.03.003; 23.06.03.001--
Tenderness08.01.08.005--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vomiting07.01.07.003--
Weight increased13.15.01.0060.000266%
Withdrawal syndrome19.07.02.005; 08.06.02.0120.000266%Not Available
Skin maceration23.03.03.016--Not Available
Application site dryness12.07.01.011; 23.03.03.024; 08.02.01.011--Not Available
Osteopenia15.02.03.003; 14.04.04.0040.000266%Not Available
Contusion24.07.06.001; 23.03.11.002; 15.03.01.008; 12.01.06.0010.000266%
Musculoskeletal discomfort15.03.04.0010.000266%Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.000930%Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages